Legis Daily

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

USA116th CongressS-3635| Senate 
| Updated: 5/6/2020
Tom Cotton

Tom Cotton

Republican Senator

Arkansas

Cosponsors (5)
Rick Scott (Republican)Mike Braun (Republican)Marsha Blackburn (Republican)Ted Cruz (Republican)Steve Daines (Republican)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Protecting Our Pharmaceutical Supply Chain from China Act of 2020 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 6, 2020
Introduced in Senate
May 6, 2020
Read twice and referred to the Committee on Finance.
Jul 13, 2020

Latest Companion Bill Action

HR 116-6482
Referred to the Subcommittee on Oversight and Investigations.
  • May 6, 2020
    Introduced in Senate


  • May 6, 2020
    Read twice and referred to the Committee on Finance.


  • July 13, 2020

    Latest Companion Bill Action

    HR 116-6482
    Referred to the Subcommittee on Oversight and Investigations.

Health

Related Bills

  • HR 116-6482: Protecting Our Pharmaceutical Supply Chain from China Act of 2020
  • S 116-3537: Protecting Our Pharmaceutical Supply Chain from China Act of 2020
AsiaBusiness expensesChinaDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth care costs and insuranceHealth programs administration and fundingHealth technology, devices, suppliesIncome tax deductionsManufacturingMilitary medicineMilitary procurement, research, weapons developmentPrescription drugsPublic contracts and procurementTrade restrictionsVeterans' medical care

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

USA116th CongressS-3635| Senate 
| Updated: 5/6/2020
Protecting Our Pharmaceutical Supply Chain from China Act of 2020 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 6, 2020
Introduced in Senate
May 6, 2020
Read twice and referred to the Committee on Finance.
Jul 13, 2020

Latest Companion Bill Action

HR 116-6482
Referred to the Subcommittee on Oversight and Investigations.
  • May 6, 2020
    Introduced in Senate


  • May 6, 2020
    Read twice and referred to the Committee on Finance.


  • July 13, 2020

    Latest Companion Bill Action

    HR 116-6482
    Referred to the Subcommittee on Oversight and Investigations.
Tom Cotton

Tom Cotton

Republican Senator

Arkansas

Cosponsors (5)
Rick Scott (Republican)Mike Braun (Republican)Marsha Blackburn (Republican)Ted Cruz (Republican)Steve Daines (Republican)

Finance Committee

Health

Related Bills

  • HR 116-6482: Protecting Our Pharmaceutical Supply Chain from China Act of 2020
  • S 116-3537: Protecting Our Pharmaceutical Supply Chain from China Act of 2020
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
AsiaBusiness expensesChinaDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth care costs and insuranceHealth programs administration and fundingHealth technology, devices, suppliesIncome tax deductionsManufacturingMilitary medicineMilitary procurement, research, weapons developmentPrescription drugsPublic contracts and procurementTrade restrictionsVeterans' medical care